Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Valerie Castillo

Nurse Practitioner Clyde, OH Nurse Practitioner

NPI 1407382179 CMS profile 10969998

455 W McPherson Hwy, B, Clyde, OH 43410

Open in the dashboard

General payments

$3,573

199 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Valerie Castillo of Clyde, OH is reported in the CMS Open Payments database as having received $3,573 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,558 85
2024 General $1,056 60
2023 General $672 38
2022 General $199 13
2021 General $89 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Valerie Castillo
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Valerie Castillo were reported at $1,558. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Valerie Castillo Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $89 $135 $40–$426 $132
2022 $199 $152 $48–$470 $149
2023 $672 $166 $54–$529 $160
2024 $1,056 $173 $55–$556 $164
2025 $1,558 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $596 39 payments
  2. Novo Nordisk Inc $469 31 payments
  3. AstraZeneca Pharmaceuticals LP $371 16 payments
  4. Teva Pharmaceuticals USA, Inc. $249 14 payments
  5. Otsuka America Pharmaceutical, Inc. $246 13 payments
  6. Lilly USA, LLC $174 11 payments
  7. Exact Sciences Corporation $134 7 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $129 6 payments
  9. ITI, Inc. $122 5 payments
  10. GlaxoSmithKline, LLC. $111 6 payments
  11. Other $972 51 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,556 198 payments
  2. Travel and Lodging $17 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $288 21 payments
  2. VRAYLAR Neuroscience $241 14 payments
  3. REXULTI $228 12 payments
  4. Austedo XR $220 12 payments
  5. RYBELSUS $212 17 payments
  6. VRAYLAR Neuroscience $198 15 payments
  7. FARXIGA $197 8 payments
  8. AIRSUPRA $148 6 payments
  9. Kerendia $129 6 payments
  10. CAPLYTA $122 5 payments
  11. Other $2,618 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 93 drugs

Part D claims

4,854

Median for Nurse Practitioner: 389

Drug cost

$455,371

Median for Nurse Practitioner: $21,885

Branded share of claims

19.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 69 $73,020
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 65 $46,772
Mounjaro Tirzepatide Brand 25 $46,517
Trulicity Dulaglutide Brand 30 $43,209
Rexulti Brexpiprazole Brand 26 $37,361
Eliquis Apixaban Brand 42 $33,652
Januvia Sitagliptin Phosphate Brand 26 $27,787
Jardiance Empagliflozin Brand 18 $25,995
Farxiga Dapagliflozin Propanediol Brand 18 $20,101
Xarelto Rivaroxaban Brand 16 $16,259

The 10 drugs with the highest cost, of 93 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$43,379

Of which drugs: $4,234

Medicare patients

189

Average age 72

Services billed

989

103 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 40%
Diabetes 31%
Chronic kidney disease 26%
Ischemic heart disease 23%
Depression 20%
Heart failure 18%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 37 37 $3,027

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $147
$147 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $98
$98 26 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $95
$95 — —
Ozempic
  • Novo Nordisk Inc $78
$78 69 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record